Combined approach of homology modeling, molecular dynamics, and docking: computer-aided drug discovery

References

[1] Arora R, Issar U, Kakkar R. Identification of novel urease inhibitors: pharmacophore modeling, virtual screening and molecular docking studies. J Biomol Struct Dyn. 2018;1–5.10.1080/07391102.2018.1546620Search in Google Scholar PubMed

[2] Badhani B, Kakkar R. In silico studies on potential MCF-7 inhibitors: a combination of pharmacophore and 3D-QSAR modeling, virtual screening, molecular docking, and pharmacokinetic analysis. J Biomol Struct Dyn. 2017;35:1950–67.10.1080/07391102.2016.1202863Search in Google Scholar PubMed

[3] Issar U, Arora R, Kumari T, Kakkar R. Combined pharmacophore-guided 3D-QSAR, molecular docking, and virtual screening on bis-benzimidazoles and ter-benzimidazoles as DNA–topoisomerase I poisons. Struct Chem. 2019;30:1–7.10.1007/s11224-018-1257-3Search in Google Scholar

[4] Spyrakis F, Cavasotto CN. Open challenges in structure-based virtual screening: receptor modeling, target flexibility consideration and active site water molecules description. Arch Biochem Biophys. 2015;583:105–19.10.1016/j.abb.2015.08.002Search in Google Scholar PubMed

[5] Cavasotto CN, Phatak SS. Homology modeling in drug discovery: current trends and applications. Drug Discov Today. 2009;14:676–83.10.1016/j.drudis.2009.04.006Search in Google Scholar PubMed

[6] Krieger E, Nabuurs SB, Vriend G. Homology modeling. Methods Biochem Anal. 2003;44:509–24.10.1002/0471721204.ch25Search in Google Scholar PubMed

[7] Meier A, Söding J. Automatic prediction of protein 3D structures by probabilistic multi-template homology modeling. PLoS Comput Biol. 2015;11:e1004343.10.1371/journal.pcbi.1004343Search in Google Scholar PubMed PubMed Central

[8] Vyas VK, Ukawala RD, Ghate M, Chintha C. Homology modeling a fast tool for drug discovery: current perspectives. Indian J Pharm Sci. 2012;74:1.10.4103/0250-474X.102537Search in Google Scholar PubMed PubMed Central

[9] Martí-Renom MA, Stuart AC, Fiser A, Sánchez R, Melo F, Šali A. Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct. 2000;29:291–325.10.1146/annurev.biophys.29.1.291Search in Google Scholar PubMed

[10] Cheng J. A multi-template combination algorithm for protein comparative modeling. BMC Struct Biol. 2008;8:18.10.1186/1472-6807-8-18Search in Google Scholar PubMed PubMed Central

[11] Liu T, Guerquin M, Samudrala R. Improving the accuracy of template-based predictions by mixing and matching between initial models. BMC Struct Biol. 2008;8:24.10.1186/1472-6807-8-24Search in Google Scholar PubMed PubMed Central

[12] Chatzou M, Magis C, Chang JM, Kemena C, Bussotti G, Erb I, et al. Multiple sequence alignment modeling: methods and applications. Brief Bioinform. 2015;17:1009–23.10.1093/bib/bbv099Search in Google Scholar PubMed

[13] Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr. 1993;26:283–91.10.1107/S0021889892009944Search in Google Scholar

[14] Sippl MJ. Recognition of errors in three-dimensional structures of proteins. Proteins Struct Funct Bioinf. 1993;17:355–62.10.1002/prot.340170404Search in Google Scholar PubMed

[15] Krissinel E, Henrick K. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr D Biol Crystallogr. 2004;60:2256–68.10.1107/S0907444904026460Search in Google Scholar PubMed

[16] Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605–12.10.1002/jcc.20084Search in Google Scholar PubMed

[17] Feng Z, Pearce LV, Xu X, Yang X, Yang P, Bumberg PM, et al. Structural insight into tetrameric hTRPV1 from homology modeling, molecular docking, molecular dynamics simulation, virtual screening, and bioassay validations. J Chem Inf Model. 2015;55:572–88.10.1021/ci5007189Search in Google Scholar PubMed PubMed Central

[18] Khoddami M, Nadri H, Moradi A, Sakhteman A. Homology modeling, molecular dynamic simulation, and docking based binding site analysis of human dopamine (D4) receptor. J Mol Model. 2015;21:36.10.1007/s00894-015-2579-3Search in Google Scholar PubMed

[19] González MA. Force fields and molecular dynamics simulations. Écolethématique de la SociétéFrançaise de la Neutronique. 2011;12:169–200.10.1051/sfn/201112009Search in Google Scholar

[20] Snow CD, Sorin EJ, Rhee YM, Pande VS. How well can simulation predict protein folding kinetics and thermodynamics? Annu Rev Biophys Biomol Struct. 2005;34:43–69.10.1146/annurev.biophys.34.040204.144447Search in Google Scholar PubMed

[21] Kandt C, Ash WL, Tieleman DP. Setting up and running molecular dynamics simulations of membrane proteins. Methods. 2007;41:475–88.10.1016/j.ymeth.2006.08.006Search in Google Scholar PubMed

[22] Sperotto MM, May S, Baumgaertner A. Modelling of proteins in membranes. Chem Phys Lipids. 2006;141:2–9.10.1016/j.chemphyslip.2006.02.024Search in Google Scholar PubMed

[23] Lindahl E, Sansom MS. Membrane proteins: molecular dynamics simulations. Curr Opin Struct Biol. 2008;18:425–31.10.1016/j.sbi.2008.02.003Search in Google Scholar PubMed

[24] Wassenaar TA, Ingólfsson HI, Böckmann RA, Tieleman DP, Marrink SJ. Computational lipidomics with insane: a versatile tool for generating custom membranes for molecular simulations. J Chem Theory Comput. 2015;11:2144–55.10.1021/acs.jctc.5b00209Search in Google Scholar PubMed

[25] Tian W, Chen C, Lei X, Zhao J, Liang J. CASTp 3.0: computed atlas of surface topography of proteins. Nucleic Acids Res. 2018;46:363–7.10.1093/nar/gky473Search in Google Scholar PubMed PubMed Central

[26] Arora R, Issar U, Kakkar R. In Silico study of the active site of Helicobacter pylori urease and its inhibition by hydroxamic acids. J Mol Graph Model. 2018;83:64–73.10.1016/j.jmgm.2018.04.018Search in Google Scholar PubMed

[27] Morris GM, Huey R, Olson AJ. Using autodock for ligand-receptor docking. Curr Protoc Bioinf. 2008;24:8–14.10.1002/0471250953.bi0814s24Search in Google Scholar PubMed

[28] Jain AN. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J Med Chem. 2003;46:499–511.10.1021/jm020406hSearch in Google Scholar PubMed

[29] Cui YL, Zhang JL, Zheng QC, Niu RJ, Xu Y, Zhang HX, et al. Structural and dynamic basis of human cytochrome P450 7B1: a survey of substrate selectivity and major active site access channels. Chem Eur J. 2013;19:549–57.10.1002/chem.201202627Search in Google Scholar PubMed

[30] Nelson DR. The cytochrome p450 homepage. Hum Genomics. 2009;4:59.10.1186/1479-7364-4-1-59Search in Google Scholar PubMed PubMed Central

[31] Dozio E, Briganti S, Vianello E, Dogliotti G, Barassi A, Malavazos AE, et al. Epicardial adipose tissue inflammation is related to vitamin D deficiency in patients affected by coronary artery disease. Nutr Metab Cardiovasc Dis. 2015;25:267–73.10.1016/j.numecd.2014.08.012Search in Google Scholar PubMed

[32] Mauf S, Penna-Martinez M, Jentzsch T, Ackermann H, Henrich D, Radeke HH, et al. Immunomodulatory effects of 25-hydroxyvitamin D3 on monocytic cell differentiation and influence of vitamin D3 polymorphisms in type 1 diabetes. J Steroid Biochem Mol Biol. 2015;147:17–23.10.1016/j.jsbmb.2014.11.001Search in Google Scholar PubMed

[33] Slominski AT, Brożyna AA, Skobowiat C, Zmijewski MA, Kim TK, Janjetovic Z, et al. On the role of classical and novel forms of vitamin D in melanoma progression and management. J Steroid Biochem Mol Biol. 2018;177:159–70.10.1016/j.jsbmb.2017.06.013Search in Google Scholar PubMed PubMed Central

[34] Jayaraj JM, Krishnasamy G, Lee JK, Muthusamy K. In silico identification and screening of CYP24A1 inhibitors: 3D QSAR pharmacophore mapping and molecular dynamics analysis. J Biomol Struct Dyn. 2018;37:1700–1714.10.1080/07391102.2018.1464958Search in Google Scholar PubMed

[35] Fan JR, Zheng QC, Cui YL, Li WK, Zhang HX. Investigation of ligand selectivity in CYP3A7 by molecular dynamics simulations. J Biomol Struct Dyn. 2015;33:2360–7.10.1080/07391102.2015.1054884Search in Google Scholar PubMed

[36] Mordvinov VA, Shilov AG, Pakharukova MY. Anthelmintic activity of cytochrome P450 inhibitors miconazole and clotrimazole: in-vitro effect on the liver fluke Opisthorchisfelineus. Int J Antimicrob Agents. 2017;50:97–100.10.1016/j.ijantimicag.2017.01.037Search in Google Scholar PubMed

[37] Pakharukova MY, Mordvinov VA. The liver fluke Opisthorchisfelineus: biology, epidemiology and carcinogenic potential. Trans R Soc Trop Med Hyg. 2016;110:28–36.10.1093/trstmh/trv085Search in Google Scholar PubMed

[38] Shukla R, Chetri PB, Sonkar A, Pakharukova MY, Mordivnov VA, Tripathi T. Identification of novel natural inhibitors of Opisthorchisfelineus cytochrome P450 using structure-based screening and molecular dynamic simulation. J Biomol Struct Dyn. 2018;36:3541–56.10.1080/07391102.2017.1392897Search in Google Scholar PubMed

[39] Fabbro D, Cowan-Jacob SW, Moebitz H. Ten things you should know about protein kinases: IUPHAR review 14. Br J Pharmacol. 2015;172:2675–700.10.1111/bph.13096Search in Google Scholar PubMed PubMed Central

[40] Rutaganira FU, Fowler ML, McPhail JA, Gelman MA, Nguyen K, Xiong A, et al. Design and structural characterization of potent and selective inhibitors of phosphatidylinositol 4 kinase IIIβ. J Med Chem. 2016;59:1830–9.10.1021/acs.jmedchem.5b01311Search in Google Scholar PubMed PubMed Central

[41] Calmettes G, Ribalet B, John S, Korge P, Ping P, Weiss JN. Hexokinases and cardioprotection. J Mol Cell Cardiol. 2015;78:107–15.10.1016/j.yjmcc.2014.09.020Search in Google Scholar PubMed PubMed Central

[42] Assouline S, Cocolakis E, Borden K. The development of novel therapies for the treatment of Acute Myeloid Leukemia (AML). Cancers. 2012;4:1161–79.10.3390/cancers4041161Search in Google Scholar PubMed PubMed Central

[43] Vijayan RS, He P, Modi V, Duong-Ly KC, Ma H, Peterson JR, et al. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors. J Med Chem. 2014;58:466–79.10.1021/jm501603hSearch in Google Scholar PubMed PubMed Central

[44] Leung AY, Man CH, Kwong YL. FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia. Leukemia. 2013;27:260.10.1038/leu.2012.195Search in Google Scholar PubMed

[45] Ke YY, Singh VK, Coumar MS, Hsu YC, Wang WC, Song JS, et al. Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification. Sci Rep. 2015;5:11702.10.1038/srep11702Search in Google Scholar PubMed PubMed Central

[46] Ramakrishnan C, Mary Thangakani A, Velmurugan D, Anantha Krishnan D, Sekijima M, Akiyama Y, et al. Identification of type I and type II inhibitors of c-Yes kinase using in silico and experimental techniques. J Biomol Struct Dyn. 2018;36:1566–76.10.1080/07391102.2017.1329098Search in Google Scholar PubMed

[47] Ul-Haq Z, Gul S, Usmani S, Wadood A, Khan W. Binding site identification and role of permanent water molecule of PIM-3 kinase: A molecular dynamics study. J Mol Graph Model. 2015;62:276–82.10.1016/j.jmgm.2015.07.004Search in Google Scholar PubMed

[48] Tanneeru K, Balla AR, Guruprasad L. In silico 3D structure modeling and inhibitor binding studies of human male germ cell-associated kinase. J Biomol Struct Dyn. 2015;33:1710–9.10.1080/07391102.2014.968622Search in Google Scholar PubMed

[49] Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253.10.1038/nrc1317Search in Google Scholar PubMed

[50] Ravanbakhsh S, Gajewski M, Greiner R, Tuszynski JA. Determination of the optimal tubulin isotype target as a method for the development of individualized cancer chemotherapy. Theor Biol Med. 2013;10:29.10.1186/1742-4682-10-29Search in Google Scholar PubMed PubMed Central

[51] Wang Y, Zhang H, Gigant B, Yu Y, Wu Y, Chen X, et al. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery. Febs J. 2016;283:102–11.10.1111/febs.13555Search in Google Scholar PubMed

[52] Kumbhar BV, Borogaon A, Panda D, Kunwar A. Exploring the origin of differential binding affinities of human tubulin isotypes αβII, αβIII and αβIV for DAMA-colchicine using homology modelling, molecular docking and molecular dynamics simulations. PLoS One. 2016;11:e0156048.10.1371/journal.pone.0156048Search in Google Scholar PubMed

[53] Aguayo-Ortiz R, Cano-González L, Castillo R, Hernández-Campos A, Dominguez L. Structure-based approaches for the design of benzimidazole-2-carbamate derivatives as tubulin polymerization inhibitors. Chem Biol Drug Des. 2017;90:40–51.10.1111/cbdd.12926Search in Google Scholar PubMed

[54] Joshi HC, Palacios MJ, McNamara L, Cleveland DW. γ-Tubulin is a centrosomal protein required for cell cycle-dependent microtubule nucleation. Nature. 1992;356:80.10.1038/356080a0Search in Google Scholar PubMed

[55] Oakley BR, Oakley CE, Yoon Y, Jung MK. γ-Tubulin is a component of the spindle pole body that is essential for microtubule function in Aspergillusnidulans. Cell. 1990;61:1289–301.10.1016/0092-8674(90)90693-9Search in Google Scholar

[56] Katsetos CD, Dráberová E, Legido A, Dráber P. Tubulin targets in the pathobiology and therapy of glioblastomamultiforme. II. γ-tubulin. J Cell Physiol. 2009;221:514–20.10.1002/jcp.21884Search in Google Scholar PubMed

[57] Niu Y, Liu T, Tse GM, Sun B, Niu R, Li HM, et al. Increased expression of centrosomal α, γ-tubulin in atypical ductal hyperplasia and carcinoma of the breast. Cancer Sci. 2009;100:580–7.10.1111/j.1349-7006.2008.01075.xSearch in Google Scholar PubMed

[58] Suri C, Naik PK. Combined molecular dynamics and continuum solvent approaches (MM-PBSA/GBSA) to predict noscapinoid binding to γ-tubulin dimer. SAR QSAR Environ Res. 2015;26:507–19.10.1080/1062936X.2015.1070200Search in Google Scholar PubMed

[59] Engles L. Review and application of serine protease inhibition in coronary artery bypass graft surgery. Am J Health Syst Pharm. 2005;62:S9–14.10.2146/ajhp050300Search in Google Scholar PubMed

[60] Siklos M, BenAissa M, Thatcher GR. Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors. Acta Pharm Sin B. 2015;5:506–19.10.1016/j.apsb.2015.08.001Search in Google Scholar PubMed PubMed Central

[61] Tanzi RE, Bertram L. Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545–55.10.1016/j.cell.2005.02.008Search in Google Scholar PubMed

[62] Dhanavade MJ, Jalkute CB, Barage SH, Sonawane KD. Homology modeling, molecular docking and MD simulation studies to investigate role of cysteine protease from Xanthomonascampestris in degradation of Aβ peptide. Comput Biol Med. 2013;43:2063–70.10.1016/j.compbiomed.2013.09.021Search in Google Scholar

[63] Sabnis YA, Desai PV, Rosenthal PJ, Avery MA. Probing the structure of falcipain-3, a cysteine protease from Plasmodium falciparum: comparative protein modeling and docking studies. Protein Sci. 2003;12:501–9.10.1110/ps.0228103Search in Google Scholar PubMed

[64] Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov. 2011;10:47.10.1038/nrd3320Search in Google Scholar PubMed

[65] Chattopadhyay A. GPCRs: Lipid-Dependent Membrane Receptors That Act as Drug Targets. Adv Biol. 2014;2014:1–12.10.1155/2014/143023Search in Google Scholar

[66] Fanelli F, De Benedetti PG. Update 1 of: computational modeling approaches to structure–function analysis of G protein-coupled receptors. Chem Rev. 2011;12:438–535.10.1021/cr100437tSearch in Google Scholar

[67] Klabunde T, Hessler G. Drug design strategies for targeting G-protein-coupled receptors. Chembiochem. 2002;3:928–44.10.1002/1439-7633(20021004)3:10<928::AID-CBIC928>3.0.CO;2-5Search in Google Scholar PubMed

[68] Rosenbaum DM, Rasmussen SG, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature. 2009;459:356.10.1038/nature08144Search in Google Scholar PubMed

[69] Schöneberg T, Schulz A, Biebermann H, Hermsdorf T, Römpler H, Sangkuhl K. Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacol Ther. 2004;104:173–206.10.1016/j.pharmthera.2004.08.008Search in Google Scholar PubMed

[70] Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov. 2006;5:993.10.1038/nrd2199Search in Google Scholar PubMed

[71] Schlyer S, Horuk R. I want a new drug: G-protein-coupled receptors in drug development. Drug Discov Today. 2006;11:481–93.10.1016/j.drudis.2006.04.008Search in Google Scholar

[72] Buhot MC. Serotonin receptors in cognitive behaviors. Curr Opin Neurobiol. 1997;7:243–54.10.1016/S0959-4388(97)80013-XSearch in Google Scholar PubMed

[73] Demirkaya K, ÖM A, Şenel B, Öncel Torun Z, Seyrek M, Lacivita E, et al. Selective 5-HT7 receptor agonists LP 44 and LP 211 elicit an analgesic effect on formalin-induced orofacial pain in mice. J Appl Oral Sci. 2016;24:218–22.10.1590/1678-775720150563Search in Google Scholar PubMed PubMed Central

[74] Medina RA, Sallander J, Benhamú B, Porras E, Campillo M, Pardo L, et al. Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity. J Med Chem. 2009;52:2384–92.10.1021/jm8014553Search in Google Scholar PubMed

[75] Jha P, Chaturvedi S, Swastika , Pal S, Jain N, Mishra AK. Improvising 5-HT7R homology model for design of high affinity ligands: model validation with docking, embrace minimization, MM-GBSA, and molecular dynamic simulations. J Biomol Struct Dyn. 2018;36:2475–94.10.1080/07391102.2017.1359907Search in Google Scholar PubMed

[76] Pease JE, Horuk R. Chemokine receptor antagonists: part 1. Expert Opin Ther Pat. 2009;19:39–58.10.1517/13543770802641346Search in Google Scholar PubMed

[77] Yoshie O, Fujisawa R, Nakayama T, Harasawa H, Tago H, Izawa D, et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1–transformed T cells. Blood. 2002;99:1505–11.10.1182/blood.V99.5.1505Search in Google Scholar PubMed

[78] Yuan Q, Bromley SK, Means TK, Jones KJ, Hayashi F, Bhan AK, et al. CCR4-dependent regulatory T cell function in inflammatory bowel disease. J Exp Med. 2007;204:1327–34.10.1084/jem.20062076Search in Google Scholar PubMed PubMed Central

[79] Gadhe CG, Kim MH. Insights into the binding modes of CC chemokine receptor 4 (CCR4) inhibitors: a combined approach involving homology modelling, docking, and molecular dynamics simulation studies. Mol Bio Syst. 2015;11:618–34.10.1039/C4MB00568FSearch in Google Scholar PubMed

[80] Sakhteman A, Khoddami M, Negahdaripour M, Mehdizadeh A, Tatar M, Ghasemi Y. Exploring 3D structure of human gonadotropin hormone receptor at antagonist state using homology modeling, molecular dynamic simulation, and cross-docking studies. J Mol Model. 2016;22:225.10.1007/s00894-016-3091-0Search in Google Scholar PubMed

[81] Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011;63:182–217.10.1124/pr.110.002642Search in Google Scholar PubMed

[82] Glavinas H, Krajcsi P, Cserepes J, Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv. 2004;1:27–42.10.2174/1567201043480036Search in Google Scholar PubMed

[83] Baumert C, Günthel M, Krawczyk S, Hemmer M, Wersig T, Langner A, et al. Development of small-molecule P-gp inhibitors of the N-benzyl 1, 4-dihydropyridine type: novel aspects in SAR and bioanalytical evaluation of multidrug resistance (MDR) reversal properties. Bioorg Med Chem. 2013;21:166–77.10.1016/j.bmc.2012.10.041Search in Google Scholar PubMed

[84] Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219.10.1038/nrd1984Search in Google Scholar PubMed

[85] Shukla S, Ohnuma S, Ambudkar SV. Improving cancer chemotherapy with modulators of ABC drug transporters. Curr Drug Targets. 2011;12:621–30.10.2174/138945011795378540Search in Google Scholar PubMed PubMed Central

[86] Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control. 2003;10:159–65.10.1177/107327480301000207Search in Google Scholar PubMed

[87] Kim Y, Chen J. Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation. Science. 2018;359:915–9.10.1126/science.aar7389Search in Google Scholar PubMed

[88] Prajapati R, Singh U, Patil A, Khomane KS, Bagul P, Bansal AK, et al. In silico model for P-glycoprotein substrate prediction: insights from molecular dynamics and in vitro studies. J Comput Aided Mol Des. 2013;27:347–63.10.1007/s10822-013-9650-xSearch in Google Scholar PubMed

[89] Prajapati R, Sangamwar AT. Translocation mechanism of P-glycoprotein and conformational changes occurring at drug-binding site: insights from multi-targeted molecular dynamics. Biochim Biophys Acta Biomembr. 2014;1838:2882–98.10.1016/j.bbamem.2014.07.018Search in Google Scholar PubMed

[90] Shahraki O, Zargari F, Edraki N, Khoshneviszadeh M, Firuzi O, Miri R. Molecular dynamics simulation and molecular docking studies of 1, 4-Dihydropyridines as P-glycoprotein’s allosteric inhibitors. J Biomol Struct Dyn. 2018;36:112–25.10.1080/07391102.2016.1268976Search in Google Scholar PubMed

[91] Syed SB, Arya H, Fu IH, Yeh TK, Periyasamy L, Hsieh HP, et al. Targeting P-glycoprotein: investigation of piperine analogs for overcoming drug resistance in cancer. Sci Rep. 2017;7:7972.10.1038/s41598-017-08062-2Search in Google Scholar PubMed PubMed Central

[92] Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer—trials and tribulations. Science. 2002;295:2387–92.10.1126/science.1067100Search in Google Scholar PubMed

[93] Ji X, Wang W, Zheng Y, Hao J, Sun M. Homology modeling and molecular dynamics simulation studies of a marine alkaline protease. Bioinform Biol Insights. 2012;6:BBI-S10663.10.4137/BBI.S10663Search in Google Scholar PubMed PubMed Central

[94] Kashyap K, Kakkar R. An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies. J Biomol Struct Dyn. 2019;1–22.10.1080/07391102.2019.1567388Search in Google Scholar PubMed

[95] Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett. 2009;277:8–21.10.1016/j.canlet.2008.08.016Search in Google Scholar PubMed

[96] Tran AD, Marmo TP, Salam AA, Che S, Finkelstein E, Kabarriti R, et al. HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions. J Cell Sci. 2007;120:1469–79.10.1242/jcs.03431Search in Google Scholar PubMed

[97] Zhang Y, Gilquin B, Khochbin S, Matthias P. Two catalytic domains are required for protein deacetylation. J Biol Chem. 2006;281:2401–4.10.1074/jbc.C500241200Search in Google Scholar PubMed

[98] Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinf. 2008;9:40.10.1186/1471-2105-9-40Search in Google Scholar PubMed PubMed Central

[99] Sixto-López Y, Bello M, Rodríguez-Fonseca RA, Rosales-Hernández MC, Martínez-Archundia M, Gómez-Vidal JA, et al. Searching the conformational complexity and binding properties of HDAC6 through docking and molecular dynamic simulations. J Biomol Struct Dyn. 2017;35:2794–814.10.1080/07391102.2016.1231084Search in Google Scholar PubMed

[100] Ibrahim Uba A, Yelekçi K. Homology modeling of human histone deacetylase 10 and design of potential selective inhibitors. J Biomol Struct Dyn. 2019;37:3627–36.10.1080/07391102.2018.1521747Search in Google Scholar PubMed

[101] Melesina J, Robaa D, Pierce RJ, Romier C, Sippl W. Homology modeling of parasite histone deacetylases to guide the structure-based design of selective inhibitors. J Mol Graph Model. 2015;62:342–61.10.1016/j.jmgm.2015.10.006Search in Google Scholar PubMed

[102] Hoops SC, Anderson KW, Merz KM, Jr. Force field design for metalloproteins. J Am Chem Soc. 1991;113:8262–70.10.1021/ja00022a010Search in Google Scholar